©Reuters.
On Thursday, William Blair raised its rating on Inogen, Inc (NASDAQ:), a medical technology company, from Market Perform to Outperform. The update follows Respironics’ announcement that it will withdraw from the US portable oxygen concentrator market by the end of February 2024. Inogen is poised to potentially capture a significant portion of the market share vacated by Respironics, formerly the second largest market operator with a 15-25% share.
The company believes that even in a bearish scenario, where the market faces challenges or a deterioration in macroeconomic conditions, Inogen could benefit from Respironics’ exit. In a more optimistic scenario, this development could lead to an increase in Inogen’s market share and improve its financial projections. Inogen has recently experienced several strategic and management changes, including the appointment of a new CEO and CFO. Despite uncertainties regarding the fundamental stability and business organization of the company, the analyst suggests that the risk-reward ratio is now favorable for investors.
The upgrade is supported by three main factors: the opportunity for Inogen to gain new market share, a valuation gap compared to competitors, and the company’s capital reserves, which are expected to sustain it for more than two years. This financial cushion could potentially bring Inogen to a point of financing or profitability.
In light of these developments, William Blair sees an opportunity for Inogen to strengthen its position in the market. The company’s valuation highlights a strategic advantage for Inogen as it navigates the current portable oxygen concentrator industry landscape.
Insights on InvestingPro
Following William Blair’s update, Inogen, Inc (NASDAQ:INGN) is under the spotlight as a company with the potential to increase its position in the portable oxygen concentrator market. InvestingPro’s data and insights provide additional insights into Inogen’s financial health and market performance that may be of interest to investors.
According to data from InvestingPro, Inogen has a market capitalization of $198.35 million, reflecting its size in the competitive landscape. While the company’s P/E ratio stands at -1.47, indicating that it is currently unprofitable, Inogen’s price to book for the trailing twelve months ended Q3 2023 is 0.86, suggesting that the stock could be underestimated in relation to its activities. Furthermore, the company has seen a significant return over the past week with a total price return of 12.42%, which could be a positive sign for short-term investors.
Tips from InvestingPro highlight that Inogen holds more cash than debt on its balance sheet, which aligns with the capital buffers mentioned by William Blair, potentially providing the company with a cushion in tough market conditions. However, analysts expect a decline in sales for the current year, which investors should take into account when evaluating the company’s growth prospects. Additionally, Inogen has been trading at a low revenue valuation multiple, which could represent an attractive entry point for value investors.
For those interested in a more in-depth analysis, there are additional InvestingPro tips for Inogen, including insights into the company’s cash burn rate and profitability forecast. To explore them further, investors can visit InvestingPro for a comprehensive view. Also, using the coupon code PRONEWS24Investors can receive an additional 10% discount on an annual or two-year Pro and Pro+ subscription, gaining access to a total of 12 InvestingPro tips that could help you make informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For further information please see our T&Cs.